BCL2 and colorectal carcinoma: As per our previous studies that demonstrated the ability of DR_MOMP to accurately predict responses of breast cancer cells to BCL-2 antagonists when combined with chemotherapy [10], we started our investigations by confirming that DR_MOMP can predict the sensitisation of CRC cell lines to genotoxic therapeutics by the BCL-2 antagonist ABT-199.